Abstract
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for newly diagnosed multiple myeloma (MM). It improves progression-free survival (PFS) and overall survival (OS) [1]. However, MM is still an incurable disease [2].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Biomedical Science & Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
